Furthermore, the PI3K pathway appears to be associated with resistance to anti-HER2 therapies [15,16], and PIK3CA mutations have been described in a variable percentage of HER2-positive breast cancer [17]. The gene discussed is PIK3CA; the disease is breast cancer.